Immunohistochemistry or IHC
Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival
Lung Cancer 2020 December 31 [Link] Puey Ling Chia, Sagun Parakh, Prudence Russell, Hui K Gan, Khashayer Asadi, Val Gebski, Carmel Murone, Marzena Walkiewicz, Zhanqi Liu, Bibhusal Thapa, Fiona E Scott, Andrew M Scott, Thomas John Abstract Aim: Conformational forms of the epidermal growth factor receptor (EGFR) are pro-tumorigenic. The prevalence and impact of conformational…
Read MoreCorrelation of MTAP Protein Expression with MTAP and CDKN2A Copy Number in Malignant Pleural Mesothelioma
Histopathology 2021 January 2 [Link] David B Chapel, Adrian M Dubuc, Jason L Hornick, Lynette M Sholl Abstract Aims: MTAP immunohistochemistry is a specific marker of CDKN2A deletion in malignant mesothelioma. However, the relationship of MTAP expression with MTAP copy number remains unexplored. Methods and results: Forty malignant pleural mesotheliomas were characterized by targeted next-generation…
Read MoreCorrelation of MTAP Protein Expression with MTAP and CDKN2A Copy Number in Malignant Pleural Mesothelioma
Histopathology 2021 January 2 [Link] David B Chapel, Adrian M Dubuc, Jason L Hornick, Lynette M Sholl Abstract Aims: MTAP immunohistochemistry is a specific marker of CDKN2A deletion in malignant mesothelioma. However, the relationship of MTAP expression with MTAP copy number remains unexplored. Methods and results: Forty malignant pleural mesotheliomas were characterized by targeted next-generation…
Read MoreMalignant pleural neoplasm with both differentiation of epithelioid mesothelioma and squamous-cell carcinoma, a rare phenomena
Diagnostic Cytopathology 2020 December 21 [Link] Ashley Re, David Shersher, Ashleigh Allen, Roland Schwarting, Shuyue Ren Abstract Malignant mesothelioma, a neoplasm arising within the serosal surfaces, has been linked closely to asbestos exposure. We present a case of 72-year-old male with a 27 year work-related history of asbestos exposure who presented with dyspnea. Chest computed…
Read MoreProgrammed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status
Pathology 2020 November 30 [Link] Eltjona Rrapaj, Lorenzo Giacometti, Paolo Spina, Michela Salvo, Guido Alessandro Baselli, Claudia Veggiani, Ottavio Rena, Elena Trisolini, Renzo Luciano Boldorini Abstract Malignant pleural mesothelioma (MPM) is often associated with a poor prognosis and options for the treatment of this disease are few. To date, the important role of the immune…
Read MoreDistant Cutaneous Metastasis Of Malignant Epithelioid Mesothelioma
Journal of Cutaneous Pathology 2020 November 30 [Link] Katrina Collins, Priyadharsini Nagarajan, Phyu P Aung Abstract Malignant mesothelioma is a locally aggressive malignancy most commonly arising from the pleural and/or peritoneal cavity. Distant cutaneous metastasis is extremely rare. Here, we describe two cases of mesothelioma metastatic to the head and neck skin. Case 1: A…
Read MoreCharacterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis
Journal of Cancer Research and Clinical Oncology 2020 November 20 [Link] Roberta Carosio, Vincenzo Fontana, Luca Mastracci, Paola Ferro, Federica Grillo, Barbara Banelli, Pier Aldo Canessa, Paolo Dessanti, Antonella Vigani, Anna Morabito, Ulrich Pfeffer, Alessandro Poggi, Silvio Roncella, Maria Pia Pistillo Abstract Purpose: Programmed death-ligand 1 (PD-L1) protein plays a central role in the antitumor…
Read MoreCan BAP1 expression loss in mesothelial cells be an indicator of malignancy?
Journal of Pathology and Translational Medicine 2020 November 9 [Link] Hanife Gulnihal Ozdemir, Sermin Coban Kokten, Nagehan Ozdemir Barisik Abstract Background: Malignant mesothelioma is a highly aggressive tumor that can be confused with a benign mesothelial lesion, especially cytomorphologic lesions. BRCA1-associated protein 1 (BAP1) acts as a tumor suppressor. In this study, we aim to…
Read MoreImpact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
Scientific Reports 2020 October 29 [Link] Sabrina Borchert, Pia-Maria Suckrau, Robert F H Walter, Michael Wessolly, Elena Mairinger, Julia Steinborn, Balazs Hegedus, Thomas Hager, Thomas Herold, Wilfried E E Eberhardt, Jeremias Wohlschlaeger, Clemens Aigner, Agnes Bankfalvi, Kurt Werner Schmid, Fabian D Mairinger Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with dismal…
Read MoreThe phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
Cytopathology 2020 October 6 [Link] Ben Davidson, Annika Jøntvedt Bock, Arild Holth, Dag Andre Nymoen Abstract Objective: To analyze the expression and clinical role of the phosphatase PTPN1 (PTP1B) in serous effusions. Methods: PTPN1 mRNA expression by quantitative RT-PCR was analyzed in 83 high-grade serous carcinoma (HGSC) and 15 malignant mesothelioma (MM) effusions. PTP1B and…
Read More